Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study To Assess The Efficacy And Safety Of Pegtibatinase Administered Subcutaneously In Addition To Standard Of Care In Participants With Classical Homocystinuria Due To Cystathionine Beta Synthase Deficiency (HARMONY)

NCT06247085 is registered in ClinicalTrials.gov with Travere Therapeutics, Inc. as lead sponsor.

NCT NCT06247085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06247085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study To Assess The Efficacy And Safety Of Pegtibatinase Administered Subcutaneously In Addition To Standard Of Care In Participants With Classical Homocystinuria Due To Cystathionine Beta Synthase Deficiency (HARMONY)
Lead sponsor
Travere Therapeutics, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
December 28, 2023
Completion date
September 30, 2027
Enrollment
70 (estimated)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

homocystinuria